Back in the 1990s, two major drug developers — SmithKline Beecham (now GlaxoSmithKline) and the publicly owned Canadian drug manufacturer Connaught Labs — were sprinting to create a vaccine for an infectious disease that seemed to pop up out of nowhere in the northeastern United States in the mid-to-late 1970s.
